NYSE:DELL
NYSE:DELLTech

Dell Technologies (DELL): Net Profit Margin Rises to 5%, Reinforcing Bullish Earnings Narratives

Dell Technologies (DELL) just published its Q3 2026 results, posting revenue of $27.0 billion and basic EPS of $2.28. The company has seen revenue trend from $24.4 billion in Q3 last year to over $29.8 billion in Q2 and now $27.0 billion this quarter. EPS has moved from $1.61 a year ago to $2.36 in Q4 and $2.28 now. Solid profit margins and steady earnings trends continue to shape an intriguing picture for investors eyeing Dell's financial momentum. See our full analysis for Dell...
NasdaqGS:EXEL
NasdaqGS:EXELBiotechs

Board Member’s $1.2 Million Share Buy Might Change the Case for Investing in Exelixis (EXEL)

Earlier this week, Exelixis board member David Johnson purchased 27,500 shares for approximately US$1.2 million, reinforcing interest in the company’s future direction. This substantial insider investment stands out as a meaningful show of confidence by a key leader, particularly given Exelixis’s focus on advancing cancer therapies. With this significant board member share purchase as a backdrop, we’ll look at how insider confidence shapes Exelixis’s broader investment narrative. AI is...
NYSEAM:NHC
NYSEAM:NHCHealthcare

A Fresh Look at National HealthCare’s (NHC) Valuation After Insider Moves and Leadership Changes

National HealthCare (NHC) is seeing increased investor attention following recent insider sales by both a director and the CEO. The company has also reported notable leadership changes and a new board appointment. See our latest analysis for National HealthCare. National HealthCare's recent insider activity and board changes have coincided with a surge in its share price, which is now near a 52-week high at $137.18. Over the past month, the share price returned 13.96%, building on a...
NasdaqGS:CRVL
NasdaqGS:CRVLHealthcare

CorVel (CRVL): Is the Current Valuation Justified After Recent Share Price Swings?

CorVel (CRVL) shares have seen mixed movement lately, with the stock down 1% over the past month but climbing about 2% for the week. Longer-term investors may be weighing performance following a drop of nearly 18% over the past 3 months. See our latest analysis for CorVel. CorVel’s share price has battled intense headwinds this year, with momentum fading and a 1-year total shareholder return of -39.2%. While this week’s modest bounce may spark some short-term hope, three-year and five-year...
NasdaqGS:PGEN
NasdaqGS:PGENBiotechs

Can Precigen's (PGEN) Revenue Surge Offset Concerns About Its Expanding Losses?

Precigen, Inc. reported financial results for the third quarter and nine months ended September 30, 2025, highlighting third-quarter revenue of US$2.92 million versus US$953,000 a year earlier, alongside a net loss of US$146.34 million compared to US$23.98 million previously. While revenue more than tripled year-over-year, Precigen’s net loss also increased significantly, leading to a wider basic loss per share from continuing operations. We’ll explore how the company’s sharp rise in revenue...
NYSE:MGM
NYSE:MGMHospitality

Assessing MGM Stock After 11.8% Rally on Digital Gaming Partnership News in 2025

Wondering if now is the right time to get into MGM Resorts International? You are not alone, as investors everywhere are questioning whether the stock's current price truly reflects its value. Shares have rebounded sharply this week, up 11.8% over the last seven days. Longer-term returns remain mixed, with the stock still down 6.9% over the past year. This recent surge comes alongside major headlines about MGM's big push into digital gaming partnerships and new property developments, both of...
NYSE:AYI
NYSE:AYIElectrical

Acuity Brands (AYI): Exploring Valuation Following Recent Outperformance and Analyst Projections

Acuity (AYI) has shown steady performance lately, and investors are keeping an eye on its stock movement with interest. Over the past week, shares have risen about 5%, and recent trends have sparked curiosity about its underlying financials. See our latest analysis for Acuity. With a 22.6% share price return so far this year and a 14.6% total shareholder return over the past 12 months, Acuity has outperformed many of its peers. The stock’s recent momentum suggests investor confidence is...
NYSE:PPL
NYSE:PPLElectric Utilities

Should PPL’s (PPL) Approved Rate Hike and New Debt Offering Change the Investment Narrative?

PPL Corporation recently declared a quarterly dividend of US$0.2725 per share payable on January 2, 2026, and announced an intention to offer US$1 billion in exchangeable senior notes due 2030 to institutional buyers. Additionally, the Pennsylvania Public Utility Commission has approved a nearly 4% increase in electric rates for PPL customers effective December 1, 2025, with a potential for further distribution rate hikes pending regulatory review. We will examine how the Pennsylvania rate...
NYSE:VNO
NYSE:VNOOffice REITs

Will JPMorgan’s Upgrade of Vornado (VNO) Shift Perceptions About NYC Office Market Resilience?

Vornado Realty Trust recently participated in the International Security Conference & Exposition at New York's Jacob Javits Center, with Vice President of Information Technology Nick Stello representing the company. Following this and recent company developments, JPMorgan analysts upgraded the stock to Neutral, citing strong business fundamentals despite broader concerns about the New York City office market. The analyst upgrade highlights how improved sentiment around Vornado’s fundamentals...
NYSE:LUCK
NYSE:LUCKHospitality

A Closer Look at Lucky Strike Entertainment’s (LUCK) Valuation Following a Recent 3% Share Price Move

Lucky Strike Entertainment (LUCK) shares moved 3% higher today, catching some attention from investors. While there wasn’t a high-profile catalyst, moves like this often have traders checking for clues about shifting sentiment or potential upcoming announcements. See our latest analysis for Lucky Strike Entertainment. While Lucky Strike Entertainment’s latest 3% jump puts some spark back in the share price, longer-term momentum has been mixed. The 7-day share price return of 8.3% suggests...
NasdaqGS:MZTI
NasdaqGS:MZTIFood

Marzetti (MZTI): Assessing Valuation After 63rd Straight Dividend Hike and New ESOP Stock Offering

Marzetti (MZTI) just announced its 63rd consecutive year of raising its quarterly cash dividend. Shareholders are set to receive $1.00 per share next month. The company also filed a $255 million shelf registration related to an ESOP stock offering. See our latest analysis for Marzetti. Marzetti’s streak of dividend hikes comes as its share price has seen moderate ups and downs over the year, with a recent dip following news of the shelf registration and ESOP offering. Over the past year,...
NasdaqGS:MLCO
NasdaqGS:MLCOHospitality

A Look at Melco Resorts & Entertainment's (NasdaqGS:MLCO) Valuation After Announcing Mocha Hotel Royal Closure

Melco Resorts & Entertainment (NasdaqGS:MLCO) has announced it will close the Mocha Hotel Royal on 28 December 2025. This marks its third Mocha club closure. The company plans to reallocate gaming machines and reassign local staff to other casino operations. See our latest analysis for Melco Resorts & Entertainment. The closure news lands as Melco’s 2025 momentum is building, with a year-to-date share price return of nearly 62% and a 44% total return over twelve months. Although there has...
NasdaqGS:KC
NasdaqGS:KCIT

A Look at Kingsoft Cloud (NasdaqGS:KC) Valuation Following Strong Q3 Revenue Growth and Reduced Net Loss

Kingsoft Cloud Holdings (NasdaqGS:KC) just released its third quarter earnings, showing notable revenue growth and a steep reduction in net loss compared to last year. This highlights clear progress in financial performance. See our latest analysis for Kingsoft Cloud Holdings. Kingsoft Cloud’s momentum has picked up notably this year, with a 77.6% one-year total shareholder return and the stock now trading at $12.45. While some short-term share price dips have occurred, the company’s...
NasdaqGS:IBOC
NasdaqGS:IBOCBanks

Assessing International Bancshares (IBOC) Valuation: Does the Discount Signal Opportunity for Investors?

International Bancshares (IBOC) has recently caught investors’ attention on valuation grounds. With the stock trading well below its estimated intrinsic value, many are taking a closer look at the company’s fundamentals and future prospects. See our latest analysis for International Bancshares. Despite a solid run over the last three years, with International Bancshares delivering a total shareholder return of 35.7%, the past year has seen sentiment cool as the 1-year total shareholder return...
NasdaqGM:RNA
NasdaqGM:RNABiotechs

Will FDA Accelerated Pathway for Delpacibart Zotadirsen Reshape Avidity Biosciences' (RNA) Rare Disease Trajectory?

In November 2025, Avidity Biosciences announced the launch of its Managed Access Program for the investigational therapy delpacibart zotadirsen for eligible Duchenne muscular dystrophy (DMD44) patients in the United States, aligning with the FDA on a 2026 accelerated approval submission pathway. This move reflects significant clinical and regulatory progress, as the therapy has earned multiple expedited designations from both U.S. and European regulators. We'll explore how securing FDA...
NasdaqGS:NVAX
NasdaqGS:NVAXBiotechs

Why Novavax (NVAX) Is Up 9.6% After Pivot to Partnerships and Higher 2025 Guidance

In November 2025, Novavax announced at the Jefferies London Healthcare Conference that it is shifting its business model toward a greater focus on research and development through partnerships, especially with Sanofi, while raising its full-year 2025 adjusted revenue projection and forecasting US$610 million in Nuvaxovid sales. An intriguing outcome is that Novavax's move away from direct COVID-19 commercial operations has led to a notable increase in licensing and royalty revenues,...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

Olema Pharmaceuticals (OLMA) Bolsters Balance Sheet but Will Fresh Capital Accelerate Oncology Innovation?

Olema Pharmaceuticals recently completed a public offering, raising approximately US$218.5 million in gross proceeds through the sale of 11,500,000 common shares at US$19.00 per share. This capital injection, accompanied by multiple changes to the lead underwriting team, further positions the company for continued progress in its targeted oncology programs. We'll explore how the strengthened balance sheet from this offering shapes Olema Pharmaceuticals' investment narrative going...
NasdaqGS:LX
NasdaqGS:LXConsumer Finance

LexinFintech (LX) Is Down 13.6% After Profit Growth and Higher Dividend—Has the Bull Case Changed?

LexinFintech Holdings Ltd. recently reported a net profit of RMB521 million for Q3 2025, achieving year-over-year profit growth, implementing a business model shift to comply with new lending regulations, and completing a US$25 million share buyback covering 2.35% of its shares. The company also raised its dividend payout ratio to 30%, reinforced risk management through enhanced AI capabilities, and reaffirmed its full-year guidance for significant net income growth. We’ll explore how...
NYSE:SOLV
NYSE:SOLVMedical Equipment

Is Solventum’s (SOLV) Billion-Dollar Buyback a Signal of Strength or Strategic Caution?

Solventum Corporation (NYSE:SOLV) recently announced a share repurchase program authorizing the repurchase of up to US$1.00 billion of its common stock, with no expiration date, and as of October 31, 2025, had approximately 173.4 million shares outstanding. This substantial buyback, combined with ongoing acquisition activity, reflects Solventum’s intent to enhance shareholder value while bolstering its position in the healthcare sector. We will now explore how the share repurchase plan...
NYSE:AEE
NYSE:AEEIntegrated Utilities

How Investors May Respond To Ameren (AEE) Requiring Long-Term Contracts From New High-Usage Customers

Earlier this month, the Missouri Public Service Commission approved a new large-load user rate structure for Ameren Missouri, requiring new, high-usage business customers to pay 100% of direct interconnection costs upfront and commit to long-term contracts. This measure aims to balance the integration of up to 2 gigawatts of new energy demand by 2032 while ensuring existing customers remain protected from costs, potentially influencing economic growth and future utility planning in...
NYSE:EHC
NYSE:EHCHealthcare

Will New Joint-Venture Hospitals Expand Encompass Health's (EHC) Reach in Key Rehabilitation Markets?

Encompass Health Corp. and Vanderbilt Health recently announced plans to open a 40-bed inpatient rehabilitation hospital in Lebanon, Tennessee, and also unveiled a separate 50-bed hospital project in Fishers, Indiana, both aimed at serving patients with complex recovery needs. These expansion efforts further expand Encompass Health's national footprint in specialized inpatient rehabilitation, highlighting strong demand for post-acute care and a continued focus on joint ventures with leading...
NasdaqGS:SYNA
NasdaqGS:SYNASemiconductor

Synaptics (SYNA) Valuation: How the Qualcomm Partnership Could Reshape the AI Sensor Landscape

Synaptics (SYNA) has just teamed up with Qualcomm Technologies to advance the integration of touch and fingerprint sensors in mobile and computing devices. This collaboration is drawing attention, particularly with the increasing focus on AI-powered user experiences. See our latest analysis for Synaptics. Synaptics’ headline-making partnership with Qualcomm arrives in the midst of a challenging year for shareholders, as the stock has posted a 1-year total shareholder return of -16.9% and a...